TR201005419A2 - Pharmaceutical composition containing valsartan. - Google Patents

Pharmaceutical composition containing valsartan.

Info

Publication number
TR201005419A2
TR201005419A2 TR2010/05419A TR201005419A TR201005419A2 TR 201005419 A2 TR201005419 A2 TR 201005419A2 TR 2010/05419 A TR2010/05419 A TR 2010/05419A TR 201005419 A TR201005419 A TR 201005419A TR 201005419 A2 TR201005419 A2 TR 201005419A2
Authority
TR
Turkey
Prior art keywords
pharmaceutical composition
composition containing
containing valsartan
valsartan
pharmaceutically acceptable
Prior art date
Application number
TR2010/05419A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/05419A priority Critical patent/TR201005419A2/en
Priority to PCT/TR2011/000168 priority patent/WO2012005709A2/en
Publication of TR201005419A2 publication Critical patent/TR201005419A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Mevcut buluş; valsartan içeren granüller ile birlikte isteğe bağlı olarak farmasötik açıdan kabul edilebilir yardımcı maddelerden oluşmuş bir farmasötik bileşim ile ilgilidir.The present invention; It relates to a pharmaceutical composition comprising granules containing valsartan and optionally pharmaceutically acceptable excipients.

TR2010/05419A 2010-07-05 2010-07-05 Pharmaceutical composition containing valsartan. TR201005419A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2010/05419A TR201005419A2 (en) 2010-07-05 2010-07-05 Pharmaceutical composition containing valsartan.
PCT/TR2011/000168 WO2012005709A2 (en) 2010-07-05 2011-07-04 Pharmaceutical composition comprising valsartan

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/05419A TR201005419A2 (en) 2010-07-05 2010-07-05 Pharmaceutical composition containing valsartan.

Publications (1)

Publication Number Publication Date
TR201005419A2 true TR201005419A2 (en) 2012-01-23

Family

ID=44741699

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/05419A TR201005419A2 (en) 2010-07-05 2010-07-05 Pharmaceutical composition containing valsartan.

Country Status (2)

Country Link
TR (1) TR201005419A2 (en)
WO (1) WO2012005709A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3342400A1 (en) * 2016-12-31 2018-07-04 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. A pharmaceutical composition comprising valsartan and chlorthalidone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE134624T1 (en) 1990-02-19 1996-03-15 Ciba Geigy Ag ACYL COMPOUNDS
TR200703568A1 (en) * 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formulations
GB0715628D0 (en) 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
CN101744813A (en) * 2010-01-21 2010-06-23 扬子江药业集团有限公司 Compound amlodipine and valsartan solid preparation and preparation method thereof

Also Published As

Publication number Publication date
WO2012005709A3 (en) 2012-07-12
WO2012005709A2 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
SMT201700008B (en) PHARMACEUTICAL COMPOSITION
IL224976A (en) Substituted 1h-indazole derivatives and pharmaceutical compositions comprising them
DK2632493T3 (en) Drug Administration Compositions
BR112013008259A2 (en) compound, pharmaceutical composition, and use of a compound
DK3246018T3 (en) PHARMACEUTICAL COMPOSITION
BR112012031226A2 (en) compound, compound use, pharmaceutical composition, and pharmaceutical composition use
BR112013011448A2 (en) compound, pharmaceutical composition, and use of compound
UA111717C2 (en) ORAL INTRODUCTION AND METHYLNALTREXON LIPOPHILIC SALTS
IT1403847B1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA AND THEIR USE.
GT201200303A (en) PHARMACEUTICAL FORMULATIONS
EE201300005A (en) Pharmaceutical composition
EA201291211A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROMORPHONE AND NALOXONE
MX344846B (en) Combination of active loaded granules with additional actives.
MX340188B (en) Manufacturing of active-free granules and tablets comprising the same.
HK1249519A1 (en) C-terminal hsp90 inhibitors and pharmaceutical compositions and usage thereof
BR112012031967A2 (en) compound, use of a compound, combination of a compound and pharmaceutical composition
EP2560614A4 (en) Pharmaceutical compositions and methods for administering the same
EA201200485A1 (en) ORAL FALLING PHARMACEUTICAL DRUG FORM CONTAINING AIPIPRAZOL
ZA201302012B (en) Low dose pharmaceutical composition
PH12014501840A1 (en) Pharmaceutical formulation having improved stability
EP2784061A4 (en) Acyl-hydrazone and oxadiazole compounds, pharmaceutical compositions containing the same and uses thereof
BR112012029461A2 (en) solifenacin-containing pharmaceutical composition
EP2544542A4 (en) Analgesic compounds, compositions, and uses thereof
FR2958166B1 (en) PHARMACEUTICAL COMPOSITIONS HIGHLY DOSE IN BIOTIN
BR112012018772A2 (en) compound, pharmaceutical composition and use of a compound